Shares of The Cigna Group are down about 3.7% in the latest session as traders reprice risk around its Evernorth Health Services segment, which houses Express Scripts, one of the largest U.S. pharmacy benefit managers (PBMs). The selling pressure is tied to renewed focus on PBM regulatory scrutiny and how quickly the industry may be forced toward more transparent, lower-rebate pricing structures that can compress near-term profitability.

The FTC disclosed a February 4, 2026 settlement with Express Scripts and affiliated entities tied to insulin-related allegations, and the agency has continued to frame PBM conduct as an enforcement priority. Even when settlements reduce headline litigation risk, they can reinforce expectations that PBMs will have to change contracting and pricing mechanics—raising uncertainty around margins, client retention, and the earnings power investors assign to Evernorth. �citeturn1search6turn1search7

Cigna’s Evernorth earnings profile has already been a sensitivity point because management has previously highlighted margin pressure during transitions toward new PBM models. With investors watching for any signal that PBM reform is accelerating—or that pricing concessions are spreading to large clients—CI can trade down on days when PBM regulation or enforcement returns to center stage. �citeturn1search0

Key near-term swing factors include any additional FTC actions involving major PBMs, employer-client commentary on rebate pass-through and pricing terms, and whether Cigna reiterates (or adjusts) its 2026 financial outlook as PBM contracting evolves. Investors will also watch for updates on Cigna’s leadership transition timeline and whether the new CEO provides fresh strategic detail on Evernorth’s path through PBM reform. �citeturn2search0